BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk...

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

MPS advises of need for better awareness of cauda equina red flag symptoms

MPS advises of need for better awareness of cauda equina red flag symptoms

May 9 2018 The Medical Protection Society is advising doctors of a revision to the NICE Clinical...

  • BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    Wednesday, 25 July 2018 14:07
  • Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Thursday, 19 July 2018 10:36
  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:22
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:51
  • MPS advises of need for better awareness of cauda equina red flag symptoms

    MPS advises of need for better awareness of cauda equina red flag symptoms

    Wednesday, 09 May 2018 16:01

Xarelto

New Real-World Data Confirm Positive Benefit-Risk Profile of Bayer’s Xarelto (rivaroxaban)® in Patients with non-valvular Atrial Fibrillation

New data from a real-world study REVISIT-US, involving almost 23,000 patients, was presented yesterday at the 2nd Annual Congress of the European Cardiac Arrhythmia Society. Reduced risk of ischemic stroke and intracranial haemorrhage (ICH) were seen in patients with non-valvular atrial fibrillation (AF) receiving Xarelto® (rivaroxaban) when compared with patients receiving warfarin.

These results confirm the positive benefit-risk profile of rivaroxaban as demonstrated in the real-world, non-interventional XANTUS study, which included over 6,500 patients across the UK, Europe, Israel and Canada. The XANTUS study expanded on Bayer’s Phase III clinical trial ROCKET AF data, and reaffirmed that rivaroxaban provides highly effective stroke prevention in both high- and lower-risk patients.

Dr Luis Felipe Graterol, Medical Director at Bayer UK said: “An estimated 1.5 million people in the UK are currently living with AF, putting them at increased risk of having a stroke. The latest findings confirm that rivaroxaban is an important prescription option to help minimise risk of stroke in patients with AF, potentially helping to reduce the burden of stroke on the healthcare system as well as on individual patients and their families.”

Atrial fibrillation, an irregular heart rhythm, affects an estimated 1.5 million people in the UK and costs the NHS over £1.8 billion in patient days spent in hospital beds alone. In the UK, approximately 150,000 people suffer from stroke each year. Atrial fibrillation is the most powerful risk factor for stroke, and thought to be directly responsible for 20% of strokes.

REVISIT-US was a retrospective claims analysis performed using US MarketScan claims data evaluating the real-world occurrence of ischemic stroke and intracranial haemorrhage (ICH) in patients with non-valvular AF taking either rivaroxaban or warfarin. In this real-world setting rivaroxaban (n=11,411) was seen to be associated with a non-significant 29% decrease in ischemic stroke accompanied by a significant 47% reduction in ICH vs. warfarin (n=11,411). Looking at the combined safety-efficacy endpoint of ICH or ischemic stroke, rivaroxaban resulted in a significant 39% reduction vs. Warfarin in REVISIT US.

AF-related strokes are easily prevented with anticoagulants and novel oral anticoagulants (NOACs) – such as rivaroxaban – provide a simplified treatment option compared to traditional therapies, such as warfarin. Rivaroxaban is an effective NOAC administered as a once-daily dose used to prevent ischaemic strokes in patients with non-valvular AF. REVISIT-US involved nearly 23,000 real-world patients in the US and adds to the extensive investigation of rivaroxaban, which by the time of its completion, is expected to include more than 275,000 patients in both clinical trials and real-world settings.


For more information about XARELTO®, visit www.xarelto.com

Clinical News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...